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Abstract
Among patients with ischemic stroke, little attention has been paid to differentiation between stroke progression
and recurrence. We assessed the role of MR imaging in predicting stroke progression, recurrent stroke, and death
within 2 years of symptom onset.
Methods: Ischemic stroke or TIA patients were prospectively enrolled. They were examined within 12 hours and
had a stroke MR completed within 24 hours of symptom onset. Patients were closely followed neurologically and
examined if there was any deterioration in neurological status. Relationships between baseline clinical and imaging
factors and outcomes were assessed. We also examined whether baseline stroke/TIA severity (NIHSS 0-5 versus
NIHSS > 5) modified these relationships.
Results: A total of 334 patients were enrolled. The overall rates of progression, 2-year recurrence, and 2-year death
were 8.7%, 8.0%, and 6.6%, respectively. Event rates were similar among patients with mild compared to more
severe strokes: 8.3% versus 9.5% (p = 0.73) for progression, and 7.3% versus 9.9% (p = 0.59) for recurrence. The
effect of baseline glucose > 8 mmol/l was consistent in predicting stroke progression, recurrent stroke and death,
regardless of baseline stroke severity. In multivariable analyses, DWI lesion and intracranial occlusion predicted
stroke progression only in the minor stroke/TIA group; symptomatic Internal Carotid Artery (ICA) stenosis predicted
stroke recurrence only in the minor stroke/TIA group.
Conclusions: In a prospective study with early assessment and imaging we have found that stroke progression is
different than stroke recurrence. Different imaging factors predict stroke progression versus stroke recurrence.
Baseline hyperglycemia, a potentially modifiable factor, consistently predicted all three outcomes (stroke
progression, recurrent stroke or death) regardless of baseline stroke severity.
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Background
P r e d i c t i n go u t c o m ea f t e ra na c u t ei s c h e m i cs t r o k ei sa n
important [1,2] both for treatment decisions and for dis-
cussion of prognosis with the patient and their family.
Even though stroke progression and stroke recurrence
are important for prognosticating patient outcome, they
are not often differentiated from each other because this
early outcome has not been assessed by careful neurolo-
gical observation during the first 48 hours.
Prediction of outcome after stroke in the longer term
includes functional outcome, identification of stroke recur-
rence or progression, and risk stratification [3]. Various
clinical factors including age, [4-6] symptom severity as
a s s e s s e db yt h eb a s e l i n eN I H S S[ 7 ]a n dt h ep r e s e n c eo f
diabetes mellitus [5,8] have been shown to correlate well
with short-term outcome [9]. Age and diabetes mellitus
have also been shown to predict recurrent stroke in the
longer term [10,11]. Both of these factors have been
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2 Transient Ischemic attack (TIA)
prognostic rule to predict early recurrent stroke [12].
Imaging is also a central part of the diagnosis and
treatment of acute ischemic stroke. In most parts of the
world computed tomography (CT) remains the most
common modality used to assess hyperacute stroke
patients, including those with TIA or minor stroke.
However, Magnetic resonance imaging (MRI) has been
shown to be better at identifying acute and chronic
ischemia than CT alone [13]. Images from CT [14,15]
and MRI [16] have been shown to correlate with short-
term prognosis. A number of groups have attempted to
create scores that combine many of the clinical and
imaging factors, to predict short-term recurrent stroke
and outcome [16,17].
None of these groups have looked at the usefulness of
imaging predictors of short-term stroke progression and
long-term recurrent stroke. It is well accepted in the
stroke community that vessel occlusion and infarction are
predictive of outcome and this may be due to stroke pro-
gression [18] or recurrent stroke [19]. Whether brain par-
enchymal imaging is also predictive of recurrent stroke in
the longer term is not well characterized. MRI may have a
particular role in the assessment of some specific patient
groups, such as the minor stroke and TIA population [20].
We therefore hypothesized that the usefulness of acute
MRI in predicting outcome would depend on whether the
event was related to stroke progression or to a distinct
recurrent stroke within 2 years of symptom onset, or to
death. We limited the analysis to clinical and imaging
parameters available acutely in the emergency room. As
well, we hypothesized that the predictive ability could be
modified by the severity of the presenting stroke or TIA.
Methods
The data described in this paper are the 2-year final
results of the prospective Vascular Imaging of acute
Stroke for Identifying predictors of clinical Outcome and
recurrent ischemic eveNts (VISION) study. The VISION
s t u d yw a sas i n g l ec e n t r ep r o s p e c t i v ec o h o r ts t u d y
approved by the conjoint health research ethics board at
t h eU n i v e r s i t yo fC a l g a r y .A l lsubjects or their surrogate
provided written consent to be included in the study.
Inclusion criteria were ischemic stroke or TIA (TIA
patients needed to have motor or speech symptoms (or
both) lasting at least five minutes) examined by a Stroke
Neurologist within 12 hours of symptom onset, age 18
years or older, have NCCT and MRI brain completed
within 24 hours of symptom onset and no pre-morbid
disability (pre-stroke historical modified Rankin Scale
(mRS) 0 or 1). All patients or next of kin provided writ-
ten consent. Patient demographics were recorded at the
time of emergency department assessment. A subset of
the minor stroke and TIA patients have been previously
published assessing short term outcomes [18,20-24].
All patients received standard acute and secondary pre-
vention treatments for stroke at the discretion of the
treating physician. This routinely includes antiplatelet
agents, statins, anthypertensives where appropriate and
anticoagulation for atrial fibrillation. Where a decision
for carotid revascularisation was made patients were trea-
t e da ss o o na sp o s s i b l ew i t ha na i mf o rt h i st ob ec o m -
pleted within 2 weeks if symptom onset in most patients.
Imaging
Patients were not enrolled until after the baseline CT so
that non-ischemic stroke diagnoses were excluded. All
patients then underwent multimodal MRI of the brain
and intra/extracranial vasculature (the ability to perform
extracranial MR angiography (MRA) was only possible
approximately half of the way through this study) within
24 hours of symptom onset using a 3-Tesla MR scanner.
To be included patients had to have completed the diffu-
sion weighted imaging (DWI) sequence of the MRI.
Sequences included sagittalT 1 ,a x i a lT 2 ,a x i a lF L A I R ,
DWI (B = 1000), Gradient echo (GRE), perfusion imaging
and 3D time-of-flight MR angiography of the intracranial
(pre- and post- gadolinium) and extracranial circulation.
All imaging was interpreted blind to clinical informa-
tion other than symptom side. CT images were reviewed
by a stroke neurologist and were assessed for evidence of
early ischemic changes. MRI of the brain was assessed by
an e u r o r a d i o l o g i s tf o rt h ep r e s e n c eo fa na c u t es t r o k e
lesion. The MRA was assessed using source images and
maximum intensity projection reformats for evidence of
an intracranial vessel occlusion, vascular occlusion or ste-
nosis, previous strokes, microbleeds (these were defined
as small regions of hypointense signal on GRE or on the
first 12 T2* PW Images obtained before gadolinium con-
trast arrival) and leukoaraiosis (this was defined as the
presence of any T2 or FLAIR white matter lesion not
related to the acute infarct). Perfusion imaging was
assessed for the presence of an abnormal area of perfu-
sion. The mean transit time (MTT) map was compared
with the DWI and assessment of the relative sizes of the
MTT map and the area of restricted diffusion was carried
out. If MTT > DWI then this was rated as “mismatch”
[21]. An overall assessment of the presence or absence of
symptomatic extracranial carotid artery disease (≥ 50%
stenosis) was made by a stroke neurologist who com-
bined all imaging and clinical data.
Clinical assessment
Clinical measurements completed included NIHSS at
baseline, 24 hours, and 90 days. All patients were admitted
to hospital and treated by a stroke neurologist who moni-
tored their course in hospital. If a patient deteriorated
neurologically (defined as neurological worsening that
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not caused by metabolic, infection or other such factors),
the patient was either classified as a recurrent stroke or as
stroke progression [18]. There was not a strict time
threshold for the diagnosis of progression, but a temporal
association with the index event was required. For exam-
ple, initial mild hemiparesis evolving to hemiplegia over
the first 24 hours was considered stroke progression rather
than recurrent stroke, unless imaging clearly showed a dis-
tinct second event remote from the presenting event. New
symptoms in a new vascular territory were considered
recurrent stroke. This included assessment of the clinical
and imaging information by two stroke neurologists inde-
pendent of the 90 day assessment and each event was clas-
sified. The area of abnormal perfusion and follow up
imaging was used to help classify events. All patients who
deteriorated had follow up imaging with either CT or
MRI.
The modified Questionnaire for verifying stroke free
status (QVSFS) [25] was completed by telephone at 6, 12,
18 and 24 months by either a physician or a registered
nurse who were blind to clinical information. If a patient
scored positive on the QVSFS for a stroke then a stroke
neurologist confirmed the diagnosis and the date of
recurrent stroke was recorded. If the patient died during
the follow up period the date of death was also recorded.
Statistical Analyses
Only variables available at first presentation in the emer-
gency room were considered in the analysis. We first
assessed the relationship between each baseline charac-
teristic and the outcomes of progression, recurrence, and
death by calculating hazard ratios (and two-sided 95%
confidence intervals) from univariate Cox proportional
hazards regressions. For the purpose of analyses, patients
were categorized into two groups, those with mild
stroke/TIA (NIHSS 0 to 5) and those with more severe
stroke/TIA (NIHSS > 5). As we hypothesized a priori
that stroke severity (defined by NIHSS) could have a
modifying effect on outcome, we included this factor
both as a main effect and interaction term in all subse-
quent regression models. Given the large number of
baseline characteristics and relatively few outcome
events, we strategically selected the remaining variables
for inclusion in the final multivariable regression model.
Only variables that had p-values < 0.05 from the univari-
ate analysis, after adjusting for multiple testing using the
False Discovery Rate correction procedure [26] and p-
values < 0.10 from the interaction with the dichotomized
NIHSS score were considered in the model. A p-value <
0.10 was chosen because it is known that tests of interac-
tion are underpowered [27]. All analyses were adjusted
for glucose level, as this was the only factor that was con-
sistently and significantly related to all three outcomes.
The proportional hazards assumption was assessed and
found to be valid for all models. Kaplan-Meier cumula-
tive failure curves were plotted to illustrate the trajec-
tories of progression, recurrence, and death. Cumulative
predicted failure curves from the Cox regressions were
plotted for recurrence by baseline characteristics. The
prognostic accuracies of them o d e l sw e r eq u a n t i f i e db y
areas under the curve (AUC) from receiver operating
characteristic (ROC) analyses. Statistical analyses were
performed using SAS 9.2 software (SAS Institute Inc).
Results
A total of 334 patients were prospectively enrolled. The
median age was 70 years (range: 18-95 years). The med-
ian time from symptom onset to arrival in the Emergency
Department was 1.9 hours (range: 0-11.4 hours) and the
median time to MRI was 7.25 hours (range: 1.3-23.4
hours). Patients were followed for a median of 23.9
months from symptom onset. Among the 334 patients,
229 (68.6%) were in the mild stroke/TIA category
(including 95 classical definition TIA’s [28]) and 105
(31.4%) in the moderate/severe category. During the
course of the 2-year study, 29 patients had stroke pro-
gression, 23 had recurrent strokes, and 20 died. Three
patients who had stroke progression died and 6 patients
with recurrent stroke died.
Figure 1 shows the overall cumulative failure curves for
progression, recurrent stroke and death. It is apparent
that progression occurred early, all within the first three
days of symptom onset, and at a rate of 8.7%. In contrast,
stroke recurrence and death occurred more gradually, at
approximately a linear rate, with 2-year risks of 8.0% and
6.6%, respectively. For both stroke progression and stroke
recurrence, the event rates were similar among patients
with mild stroke/TIA comparedt om o r es e v e r es t r o k e s :
8.3% versus 9.5% (p-value = 0.73) for progression, and
7.3% versus 9.9% (p-value = 0.59) for recurrence. How-
ever, patients with more severe TIA/strokes had a higher
death rate than those with mild TIA/strokes, 16.8%
versus 1.9% (p-value < 0.001).
Univariate analysis of the clinical and imaging factors
and outcomes of progression, recurrent stroke, and
death are shown in Table 1. Different factors are rele-
vant predictors of the three different outcomes. DWI
lesion, intracranial occlusion and symptomatic ICA ste-
nosis predicted stroke progression. Male sex, history of
diabetes mellitus, microbleeds, and symptomatic ICA
stenosis predicted recurrent strokes. NIHSS, age, and
microbleeds predicted death. Most notably, admission
hyperglycemia was the only factor that was consistently
and highly predictive of all three outcomes, and it was
unmodified by stroke severity (p-value for tests of inter-
action = 0.56, 0.40, and 0.40 for progression, recurrence,
and death, respectively).
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progression, recurrent stroke and death within 2 years,
stratified by stroke severity. In predicting progression,
stroke severity modified the relationship with DWI
lesion and intracranial occlusion. Both factors were only
predictive of stroke progression among patients with
mild strokes/TIAs (p-value for tests of interaction =
0.13 and 0.022, respectively) but not in patients with
NIHSS > 5. The two imaging factors increased the AUC
prognostic accuracy from 0.59 (with only NIHSS and
glucose in the model) to 0.79 when imaging was
included.
In predicting recurrent stroke, stroke severity modified
the relationship with symptomatic ICA stenosis. The
single factor was predictive of recurrent stroke in
patients with mild strokes/TIAs (p-value for tests of
interaction = 0.058), but not in patients with NIHSS >
5. The single imaging factor increased the AUC prog-
nostic accuracy from 0.64 (with only NIHSS and glucose
in the model) to 0.77 when imaging was included. No
imaging factors were predictive of death. Only older age
predicted death, and only for patients with severe
(NIHSS > 5) strokes/TIAs (p-value for tests of interac-
tion = 0.062). Age did not significantly increase the
prognostic accuracy for death (AUC of 0.87 versus 0.80
for NIHSS and glucose alone).
Figure 2 and 3 show the cumulative predicted failure
curves from Cox regression for the outcome of recur-
rence by baseline glucose level and by degree of sympto-
matic ICA stenosis, respectively. Admission
hyperglycemia has a detrimental effect on stroke recur-
rence, regardless of stroke severity. However, stroke
recurrence was higher only among patients with a mild
stroke/TIA who had moderate-to-severe ICA stenosis
(50 to 100%).
Discussion
The clinical and imaging factors that predict stroke pro-
gression and recurrent stroke at 2 years are different.
We have, with careful neurological assessment, distin-
guished between recurrent stroke and stroke progres-
sion. Baseline hyperglycemia was important for all
outcomes of stroke progression, recurrent stroke and
death within 2 years in both groups of patients. We
found that the overall rates of stroke progression and
recurrent stroke were similar between the TIA/minor
stroke and the moderate/severe groups, although there
were differences in the predictors between the 2 groups.
Different imaging parameters are useful at different
times. Stroke progression is an acute phenomenon
occurring most commonly in the first 24 hours. The
presence of a DWI lesion and/or intracranial vascular
occlusion predicted stroke progression in the minor
stroke/TIA population. This argues for acute MR ima-
ging of these patients in the first 24 hours. Among
patients with an intracranial occlusion symptom pro-
gression may be due to failure of collaterals or less com-
monly to recurrent embolus. In the minor stroke/TIA
population the addition of the imaging parameters
described above, to the clinical factors increases the
AUC substantially for predicting both stroke progression
and recurrent stroke. This suggests that early MRI
should be the modality of choice for TIA and minor
stroke. Assessing the imaging predictors of recurrent
stroke we find that carotid stenosis is most likely a
reflection of the underlying risk factors for vascular dis-
ease. Carotid stenosis is well understood as a strong pre-
dictor of long term stroke risk [29].
A l lp a t i e n t si nt h i sp r o t o col-driven study were
enrolled by stroke neurologists, underwent detailed clin-
ical and imaging evaluations, and were followed pro-
spectively. The advantage of this is that we were able to
distinguish between stroke progression and recurrent
stroke. Stroke progression and recurrent stroke appear
to be different in mechanism as well as timing [30]. Pro-
gression happens extremely early and is related to the
presenting event (which is why imaging early matters);
however, recurrence very early is less common and is
more relevant as a longer term event. Over 2 years,
recurrence is related to risk factors for vascular disease.
I n t e r e s t i n g l yw ef o u n das i m i l a rs t r o k ep r o g r e s s i o na n d
recurrent stroke rate between the minor stroke/TIA and
the moderate/severe stroke populations.
Our results are consistent with the previous literature
that has shown that long-term prognosis after stroke is
more dependent on the underlying vascular risk factors
(including stroke mechanism) than factors related to the
presenting event [31-34]. This has not been previously
shown for hyperacute MRI. Additional advantages of
Figure 1 Kaplan-Meier cumulative failure curves for the
outcome of progression, recurrence and death.
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Page 4 of 8Table 1 Baseline Clinical and Imaging Characteristics and Univariate Analysis from Cox Proportional Hazards Regression
Percentage of Group
(N = 334)
Progression Hazard Ratio
(95% CI)
P-value
(FDR)
Recurrence Hazard Ratio
(95% CI)
P-value
(FDR)
Death Hazard Ratio
(95% CI)
P-value
(FDR)
NIHSS > 5 31.4 1.1 (0.5, 2.4) 0.74 1.3 (0.5, 3.0) 0.59 9.3 (3.1, 27.8) < 0.001
Age > 75 years 34.4 0.8 (0.4, 1.9) 0.68 (0.86) 1.6 (0.7, 3.7) 0.26 (0.58) 8.3 (2.8, 24.8) < 0.001
(0.001)
Male sex 58.1 1.0 (0.5, 2.2) 0.91 (0.95) 3.4 (1.1, 9.9) 0.026 (0.07) 0.8 (0.3, 2.1) 0.72 (0.77)
Hypertension history 60.0 1.1 (0.5, 2.3) 0.80 (0.86) 1.9 (0.8, 4.9) 0.16 (0.31) 1.3 (0.5, 3.1) 0.63 (0.77)
Diabetes mellitus history 15.0 1.9 (0.8, 4.4) 0.14 (0.23) 2.6 (1.1, 6.3) 0.035 (0.12) 1.9 (0.7, 5.3) 0.20 (0.42)
Coronary artery disease history 12.9 0.0 (—, —) 0.98 (1.00) 0.6 (0.1, 2.6) 0.52 (0.79) 1.2 (0.3, 4.0) 0.79 (0.77)
Systolic BP > 140 or diastolic
BP > 90
69.5 2.1 (0.8, 5.6) 0.12 (0.22) 1.3 (0.5, 3.2) 0.62 (0.79) 2.5 (0.7, 8.7) 0.14 (0.30)
Glucose > 8 mmol/L 18.0 2.5 (1.2, 5.4) 0.019 (0.06) 3.9 (1.7, 8.8) 0.001
(0.014)
3.2 (1.3, 7.7) 0.012 (0.06)
Treated with thrombolytic
therapy
21.3 0.4 (0.1, 1.4) 0.15 (0.23) 1.0 (0.4, 2.8) 0.94 (0.95) 2.4 (1.0, 6.0) 0.051 (0.13)
Acute stroke on NCCT 34.1 1.4 (0.7, 2.9) 0.39 (0.53) 0.8 (0.3, 2.1) 0.71 (0.81) 1.2 (0.5, 3.1) 0.62 (0.77)
DWI lesion (one or more vs
none)
68.0 6.5 (1.5, 27.3) 0.011 (0.013 2.3 (0.8, 6.8) 0.13 (0.30) 1.9 (0.6, 5.7) 0.25 (0.44)
Intracranial occlusion 21.6 5.4 (2.6, 11.3) < 0.001 (<
0.001)
0.8 (0.3, 2.3) 0.69 (0.79) 1.6 (0.6, 4.2) 0.32 (0.57)
DWI/MTT mismatch 21.3 2.0 (0.9, 4.3) 0.075 (0.17) 1.1 (0.4, 2.9) 0.90 (0.95) 1.3 (0.5, 3.5) 0.65 (0.77)
White matter disease on MRI 70.0 1.1 (0.5, 2.6) 0.75 (0.86) 2.0 (0.7, 6.0) 0.19 (0.31) 3.9 (0.9, 16.9) 0.067 (0.13)
Microbleeds 23.6 1.7 (0.8, 3.7) 0.17 (0.23) 2.2 (1.0, 5.1) 0.061 (0.21) 2.9 (1.2, 6.8) 0.021 (0.10)
Symptomatic ICA stenosis 15.3 3.1 (1.4, 6.6) 0.004 (0.013) 3.3 (1.4, 7.7) 0.007 (0.05) 1.5 (0.5, 4.4) 0.48 (0.77)
FDR = False Discovery Rate p-value adjusting for multiple testing.
Test of interaction with dichotomized NIHSS score p-value: Progression (DWI lesion = 0.10, Intracranial occlusion = 0.011); Recurrence (Symptomatic ICA stenosis = 0.05); Death (Age = 0.049).
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8having an MRI completed early, such as confirmation of
ischemia, identifying the vascular territory affected and
assessment of the final etiology of the stroke or TIA
[35], all may alter management, suggest to us that MR
should be the modality of choice of the TIA/minor
stroke population.
We have shown the importance of hyperglycemia on the
prediction of stroke progression, recurrent stroke and
death within 2 years. Hyperglycemia may be the result of
an acute stress response or be associated with previously
undiagnosed or latent diabetes mellitus. In our view, the
relationship with recurrent stroke at 2 years makes the lat-
ter more likely in this population. Hyperglycemia is an
important poor prognostic factor in acute stroke [36] and
it remains an important area for further study. Recent pre-
liminary trials of aggressively targeting normoglycemia
have been negative or neutral, but this is an important area
for further study as it is a potentially modifiable factor [37].
There are some limitations to this work. This is a single
centre observational study and these results need replicated
in other centres. The cause of death was not captured in
this study and so we cannot assess how many patients died
f r o mav a s c u l a rd e a t h .S o m eg r o u p sh a v ea d v o c a t e dt h e
use of DWI volumes to predict outcome after stroke, [38]
but there have been mixed results in the literature with
regards this [39]. We chose only to assess factors available
on initial assessment in the emergency room and as DWI
volumes are not routinely measured in clinical practice we
did not include this in our analysis. Another limitation is
that the ability to image the neck vessels with MR angio-
graphy was only available approximately half way through
the study, so assessment of neck vessels was made using
various combinations of imaging modalities; including MR
angiography, CT angiography and Carotid Doppler.
Although this is a limitation it is the reality of non invasive
imaging. Also the relatively smaller number of patients in
the moderate/severe group compared to the minor stroke/
TIA group is one possible explanation for not finding MRI
parameters that predict outcome in this subgroup.
Conclusions
I nap r o s p e c t i v es t u d yw eh a v ef o u n dt h a tt h ea d d i n g
imaging results to clinical parameters increases the
Table 2 Final Multivariable Cox Proportional Hazards Regression Models for Progression, Recurrence, and Death
NIHSS 0 to 5 (N = 229) NIHSS > 5 (N = 105)
Hazard Ratio (95% CI) P-value (FDR) Hazard Ratio (95% CI) P-value (FDR)
Progression (19 and 10 events)
DWI lesion (one or more vs none) 12.4 (1.6, 93.3) 0.014 (0.028) 1.4 (0.2, 11.1) 0.75 (0.82)
Intracranial occlusion 11.3 (4.4, 29.2) < 0.001 (< 0.001) 1.9 (0.5, 6.5) 0.33 (0.53)
Recurrence (15 and 8 events)
Symptomatic ICA stenosis 5.6 (2.0, 15.6) < 0.001 (0.004) 0.6 (0.1, 4.9) 0.64 (0.82)
Death (4 and 16 events)
Age > 75 years 1.3 (0.1, 13.7) 0.82 (0.82) 19.5 (2.6, 148.3) 0.004 (0.011)
Each analysis was adjusted for glucose.
FDR = False Discovery Rate p-value adjusting for multiple testing.
Figure 2 Cumulative predicted failure curves from Cox regression
for the outcome of recurrence by baseline glucose level.
Figure 3 Cumulative predicted failure curves from Cox
regression for the outcome of recurrence by baseline NIHSS
score and degree of symptomatic ICA stenosis, adjusting for
baseline glucose level.
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gression. We also found that the imaging features that
were important differed for recurrent stroke and stroke
progression. This work is hypothesis generating and
needs replicated in other centres.
Acknowledgements
We acknowledge the members of the VISION study group for their help in
enrolment and data collection for this study. The VISION study group
includes: Carol Kenney, Karla Ryckborst, Marie McClelland, Andrea Cole-
Haskayne, Nancy Newcommon, Kathy Werdel, Andrea Krol, Dr James N.
Scott, Dr Jayanta Roy, Dr Alastair M. Buchan, Dr Suresh Subramanian, Dr
Chul-Ho Sohn, Dr Philip A. Barber, Dr Richard Frayne, Dr Ross Mitchell, Dr
Tim Watson, Dr Nic Weir, Dr Young-Bin Choi, Dr Imanuel Dzialowski, Dr
Volker Puetz, Dr Vanessa Palumbo, Dr John Martin Boulanger, Dr James
Kennedy, Dr Siva Kumar, Dr Jessica Simon, and Dr Anna Tomanek.
Funding Sources
This study was supported by grant funding from the Canadian Institutes
for Health Research (CIHR MOP-118096) and Heart and Stroke Foundation
(HSF) of Alberta, NWT and Nunavut. The 3.0 T MR Scanner in the Seaman
Family MR Research Centre used in this study was partially funded by
Canada Foundation for Innovation. Acute stroke imaging was also
supported by the Alberta Foundation for Health Research. Drs Coutts,
Demchuk, Eliasziw and Hill received salary support from the Alberta
Heritage Foundation for Medical Research. Dr Coutts received the Heart
and Stroke Foundation of Canada Distinguished Clinician Scientist award,
supported in partnership with the CIHR Institute of Circulatory and
Respiratory Health and AstraZeneca Canada Inc. Dr Eliasziw received salary
support from the Natural Sciences and Engineering Research Council of
Canada.
Author details
1Room C1261, Calgary Stroke Program, Department of Clinical Neurosciences
and Radiology, University of Calgary, 1403 29th St NW, Calgary, AB, T2N 2T9,
Canada.
2Calgary Stroke Program, Department of Clinical Neurosciences,
Radiology, Community Health Sciences, and Medicine, University of Calgary,
1403 29th St NW, Calgary, AB, T2N 2T9, Canada.
3Department of Community
Health Sciences, University of Calgary, 1403 29th St NW, Calgary, AB, T2N
2T9, Canada.
4Calgary Stroke Program, Department of Clinical Neurosciences,
University of Calgary, 1403 29th St NW, Calgary, AB, T2N 2T9, Canada.
5Calgary Stroke Program, Department of Clinical Neurosciences and
Radiology, University of Calgary, 1403 29th St NW, Calgary, AB, T2N 2T9,
Canada.
Authors’ contributions
SC conceived the study, participated in the study design and coordination
and drafted the manuscript. MH participated in the study design, helped
with the statistical analysis and helped to draft the manuscript. ME
participated in the design of the study and performed the statistical analysis.
AMD conceived the study, participated in its design and coordination and
helped to draft the manuscript. KF participated in the study design and
coordination and edited the manuscript. All authors read and approved the
final manuscript.
Competing interests
The authors declare that they have no competing interests.
Received: 3 November 2010 Accepted: 23 April 2011
Published: 23 April 2011
References
1. Weimar C, Ziegler A, Konig IR, Diener HC: Predicting functional outcome
and survival after acute ischemic stroke. J Neurol 2002, 249(7):888-895.
2. Chambers BR, Norris JW, Shurvell BL, Hachinski VC: Prognosis of acute
stroke. Neurology 1987, 37(2):221-225.
3. Sacco RL, Wolf PA, Kannel WB, McNamara PM: Survival and recurrence
following stroke. The Framingham study. Stroke 1982, 13(3):290-295.
4. Henon H, Godefroy O, Leys D, Mounier-Vehier F, Lucas C, Rondepierre P,
Duhamel A, Pruvo JP: Early predictors of death and disability after acute
cerebral ischemic event. Stroke 1995, 26(3):392-398.
5. Johnston KC, Connors AF Jr, Wagner DP, Knaus WA, Wang X, Haley EC Jr: A
predictive risk model for outcomes of ischemic stroke. Stroke 2000,
31(2):448-455.
6. Nakayama H, Jorgensen HS, Raaschou HO, Olsen TS: The influence of age
on stroke outcome. The Copenhagen Stroke Study. Stroke 1994,
25(4):808-813.
7. Adams HP Jr, Davis PH, Leira EC, Chang KC, Bendixen BH, Clarke WR,
Woolson RF, Hansen MD: Baseline NIH Stroke Scale score strongly
predicts outcome after stroke: A report of the Trial of Org 10172 in
Acute Stroke Treatment (TOAST). Neurology 1999, 53(1):126-131.
8. Jorgensen H, Nakayama H, Raaschou HO, Olsen TS: Stroke in patients with
diabetes. The Copenhagen Stroke Study. Stroke 1994, 25(10):1977-1984.
9. Weimar C, Konig IR, Kraywinkel K, Ziegler A, Diener HC: Age and National
Institutes of Health Stroke Scale Score within 6 hours after onset are
accurate predictors of outcome after cerebral ischemia: development
and external validation of prognostic models. Stroke 2004, 35(1):158-162.
10. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS,
Stewart-Wynne EG: Long-term risk of first recurrent stroke in the Perth
Community Stroke Study. Stroke 1998, 29(12):2491-2500.
11. Appelros P, Nydevik I, Viitanen M: Poor outcome after first-ever stroke:
predictors for death, dependency, and recurrent stroke within the first
year. Stroke 2003, 34(1):122-126.
12. Johnston SC, Rothwell PM, Nguyen-Huynh MN, Giles MF, Elkins JS,
Bernstein AL, Sidney S: Validation and refinement of scores to predict
very early stroke risk after transient ischaemic attack. Lancet 2007,
369(9558):283-292.
13. Chalela JA, Kidwell CS, Nentwich LM, Luby M, Butman JA, Demchuk AM,
Hill MD, Patronas N, Latour L, Warach S: Magnetic resonance imaging and
computed tomography in emergency assessment of patients with
suspected acute stroke: a prospective comparison. Lancet 2007,
369(9558):293-298.
14. Barber PA, Demchuk AM, Zhang J, Buchan AM: Validity and reliability of a
quantitative computed tomography score in predicting outcome of
hyperacute stroke before thrombolytic therapy. ASPECTS Study Group.
Alberta Stroke Programme Early CT Score. Lancet 2000,
355(9216):1670-1674.
15. Schramm P, Schellinger PD, Klotz E, Kallenberg K, Fiebach JB, Kulkens S,
Heiland S, Knauth M, Sartor K: Comparison of perfusion computed
tomography and computed tomography angiography source images
with perfusion-weighted imaging and diffusion-weighted imaging in
patients with acute stroke of less than 6 hours’ duration. Stroke 2004,
35(7):1652-1658.
16. Baird AE, Dambrosia J, Janket S, Eichbaum Q, Chaves C, Silver B, Barber PA,
Parsons M, Darby D, Davis S, et al: A three-item scale for the early
prediction of stroke recovery. Lancet 2001, 357(9274):2095-2099.
17. Johnston KC, Connors AF Jr, Wagner DP, Haley EC Jr: Predicting outcome
in ischemic stroke: external validation of predictive risk models. Stroke
2003, 34(1):200-202.
18. Coutts SB, Hill MD, Campos CR, Choi YB, Subramaniam S, Kosior JC,
Demchuk AM: Recurrent events in transient ischemic attack and minor
stroke: what events are happening and to which patients? Stroke 2008,
39(9):2461-2466.
19. Lavallee PC, Meseguer E, Abboud H, Cabrejo L, Olivot JM, Simon O,
Mazighi M, Nifle C, Niclot P, Lapergue B, et al: A transient ischaemic attack
clinic with round-the-clock access (SOS-TIA): feasibility and effects.
Lancet Neurol 2007, 6(11):953-960.
20. Coutts SB, Simon JE, Eliasziw M, Sohn CH, Hill MD, Barber PA, Palumbo V,
Kennedy J, Roy J, Gagnon A, et al: Triaging transient ischemic attack and
minor stroke patients using acute magnetic resonance imaging. Ann
Neurol 2005, 57(6):848-854.
21. Coutts SB, Eliasziw M, Hill MD, Scott JN, Subramaniam S, Buchan AM,
Demchuk AM: An improved scoring system for identifying patients at
high early risk of stroke and functional impairment after an acute
transient ischemic attack or minor stroke. Int J Stroke 2008, 3(1):3-10.
22. Coutts SB, Hill MD, Simon JE, Sohn CH, Scott JN, Demchuk AM: Silent
ischemia in minor stroke and TIA patients identified on MR imaging.
Neurology 2005, 65(4):513-517.
Coutts et al. BMC Cardiovascular Disorders 2011, 11:18
http://www.biomedcentral.com/1471-2261/11/18
Page 7 of 823. Sylaja PN, Coutts SB, Krol A, Hill MD, Demchuk AM: When to expect
negative diffusion-weighted images in stroke and transient ischemic
attack. Stroke 2008, 39(6):1898-1900.
24. Sylaja PN, Coutts SB, Subramaniam S, Hill MD, Eliasziw M, Demchuk AM:
Acute ischemic lesions of varying ages predict risk of ischemic events in
stroke/TIA patients. Neurology 2007, 68(6):415-419.
25. Jones WJ, Williams LS, Meschia JF: Validating the Questionnaire for
Verifying Stroke-Free Status (QVSFS) by neurological history and
examination. Stroke 2001, 32(10):2232-2236.
26. Benjamini Y, Hochberg Y: Controlling the False Discovery Rate: a practical
and powerful approach to multiple testing. Journal of the Royal Statistical
Society B 1995, 57:289-300.
27. Selvin S: Variation and Bias. In: Statistical Analysis of Epidemiologic Data. 3
edition. Oxford University Press; 2004, 54-69.
28. The World Health Organization MONICA Project (monitoring trends and
determinants in cardiovascular disease): a major international
collaboration. WHO MONICA Project Principal Investigators. J Clin
Epidemiol 1988, 41(2):105-114.
29. Rothwell PM, Eliasziw M, Gutnikov SA, Fox AJ, Taylor DW, Mayberg MR,
Warlow CP, Barnett HJ: Analysis of pooled data from the randomised
controlled trials of endarterectomy for symptomatic carotid stenosis.
Lancet 2003, 361(9352):107-116.
30. Toni D, Fiorelli M, Gentile M, Bastianello S, Sacchetti ML, Argentino C,
Pozzilli C, Fieschi C: Progressing neurological deficit secondary to acute
ischemic stroke. A study on predictability, pathogenesis, and prognosis.
Arch Neurol 1995, 52(7):670-675.
31. Hankey GJ, Slattery JM, Warlow CP: Transient ischaemic attacks: which
patients are at high (and low) risk of serious vascular events? J Neurol
Neurosurg Psychiatry 1992, 55(8):640-652.
32. Hankey GJ: Long-term outcome after ischaemic stroke/transient
ischaemic attack. Cerebrovasc Dis 2003, 16(Suppl 1):14-19.
33. Kernan WN, Viscoli CM, Brass LM, Makuch RW, Sarrel PM, Roberts RS,
Gent M, Rothwell P, Sacco RL, Liu RC, et al: The stroke prognosis
instrument II (SPI-II): A clinical prediction instrument for patients with
transient ischemia and nondisabling ischemic stroke. Stroke 2000,
31(2):456-462.
34. van Wijk I, Kappelle LJ, van Gijn J, Koudstaal PJ, Franke CL, Vermeulen M,
Gorter JW, Algra A: Long-term survival and vascular event risk after
transient ischaemic attack or minor ischaemic stroke: a cohort study.
Lancet 2005, 365(9477):2098-2104.
35. Lee LJ, Kidwell CS, Alger J, Starkman S, Saver JL: Impact on stroke subtype
diagnosis of early diffusion-weighted magnetic resonance imaging and
magnetic resonance angiography. Stroke 2000, 31(5):1081-1089.
36. Poppe AY, Majumdar SR, Jeerakathil T, Ghali W, Buchan AM, Hill MD:
Admission hyperglycemia predicts a worse outcome in stroke patients
treated with intravenous thrombolysis. Diabetes Care 2009, 32(4):617-622.
37. Gray CS, Hildreth AJ, Sandercock PA, O’Connell JE, Johnston DE,
Cartlidge NE, Bamford JM, James OF, Alberti KG: Glucose-potassium-insulin
infusions in the management of post-stroke hyperglycaemia: the UK
Glucose Insulin in Stroke Trial (GIST-UK). Lancet Neurol 2007, 6(5):397-406.
38. Thijs VN, Lansberg MG, Beaulieu C, Marks MP, Moseley ME, Albers GW: Is
early ischemic lesion volume on diffusion-weighted imaging an
independent predictor of stroke outcome? A multivariable analysis.
Stroke 2000, 31(11):2597-2602.
39. Hand PJ, Wardlaw JM, Rivers CS, Armitage PA, Bastin ME, Lindley RI,
Dennis MS: MR diffusion-weighted imaging and outcome prediction
after ischemic stroke. Neurology 2006, 66(8):1159-1163.
Pre-publication history
The pre-publication history for this paper can be accessed here:
http://www.biomedcentral.com/1471-2261/11/18/prepub
doi:10.1186/1471-2261-11-18
Cite this article as: Coutts et al.: Final 2 year results of the vascular
imaging of acute stroke for identifying predictors of clinical outcome and
recurrent ischemic eveNts (VISION) study. BMC Cardiovascular Disorders 2011
11:18.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Coutts et al. BMC Cardiovascular Disorders 2011, 11:18
http://www.biomedcentral.com/1471-2261/11/18
Page 8 of 8